Technical / White Paper

Analysis of Biopharmaceuticals to Conform to ICHQ6B

Format: PDF file | Document type: Technical / White Paper | Promoted Content

This Technical / White Paper has been written by RSSL , and any views and opinions expressed do not necessarily reflect those of


Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%.

In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules.

Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.

Latest content from RSSL

show more

Extractables and leachables analysis of pharmaceutical products

Content provided by RSSL

Extractables and leachables analysis of pharmaceutical products

A crucial undertaking when releasing pharmaceutical products for the market, is to determine the purity of the final product, necessitating the need to determine its impurity profile. Traditionally, this was concerned only with those impurities arising...

The impact of particles on pharmaceuticals

Content provided by RSSL

The impact of particles on pharmaceuticals

Sometimes it's the smallest details that have the biggest impact on pharmaceutical performance. That's certainly true when it comes down to the properties of particles and their impact on pharmaceutical performance. Subtle changes in particle...

Related resources from RSSL

Show more

Supplier info centre